Commemorating its 70th anniversary in Taiwan AstraZeneca invests NTD 1 billion over the next three years to support patients and biopharmaceutical innovation in Taiwan

    AstraZeneca, selected as the world’s most innovative pharmaceutical company [1], today announced an additional investment of NTD 1 billion over the next three years in Taiwan. This will enable nearly 3 fold increase in clinical R&D expenditure, support the rollout of ten new medicines and create 140 high quality jobs in Taiwan by 2021. In addition to the investment, AstraZeneca will sign a Letter of Intent with BioHub Taiwan (National Biotechnology Research Park) and Program for Translational Innovation of Biopharmaceutical Development-Technology Supporting Platform Axis (TSPA) to support the development of Taiwan’s biopharmaceutical industry.

   The additional investment and the Letter of Intent demonstrate AstraZeneca’s continuous commitment to patients and healthcare in Taiwan, which first began 70 years ago when in 1948 AstraZeneca was one of the first international companies to establish an office in Taipei.

AstraZeneca has been committed to delivering science to patients in Taiwan since 1948

     AstraZeneca’s bond with Taiwan started when it supported the struggle against malaria with the introduction of a new anti-malaria medicine Paludrine in the 1940’s. Since then, AstraZeneca has been equipping healthcare professionals in Taiwan with life-changing medicines based on Nobel-prize winning science.
     Notable milestones include the introduction of the world’s first amino amide-type local anesthetic, the world’s first successful beta-blocker, and the world’s most successful hormonal medicine for breast cancer. Many of these medicines are part of the WHO List of Essential Medicines, the most effective and the safest medicines needed in a health system.

AstraZeneca works on scientific solutions to Taiwan’s healthcare challenges

    At present, AstraZeneca’s innovative medicines directly address four out of Taiwan’s seven leading causes of death: cancer, cardiovascular diseases, diabetes and respiratory disease.[2]
In addition, to help enhance healthcare for Taiwan’s ca. 2 million asthma and ca. 2 million diabetes patients, AstraZeneca has initiated two innovative healthcare delivery partnerships:
       Healthy Lung: The Taiwan Society of Pulmonary and Critical Care Medicine (TSPCCM) and AstraZeneca are supporting the launch of 500 Asthma Centres of Excellence by end of 2018. These aim to enable early diagnosis, educate patients about their disease and augment the capabilities of healthcare professionals.

       Early action in Diabetes: The Taiwanese health technology start-up Health2Sync and AstraZeneca will support 500,000 diabetes patients with a smart disease control platform with the aim of achieving controlled glucose levels (HbA1c level <7%) for at least half of them by 2020.

     “At AstraZeneca we are deeply committed to pushing the boundaries of science to create life-changing medicine. Partnerships like Healthy Lung and Early Action in Diabetes aim to increase patients’ quality of life, prevent mortality and reduce healthcare expenditure.” said Joris Silon, Asia Area President.
        In the last five years AstraZeneca has invested over NTD 1.4 billion in clinical R&D in Taiwan to help develop precision medicines that suits our local genetic profile. In Taiwan, AstraZeneca ranks number 2 in clinical research intensity overall and is the number one initiator of clinical trials on lung   cancer [3]—Taiwan’s number one leading cause of death.[4]  AstraZeneca is proud to work with 37 world-class Taiwanese clinical research partners to develop new solutions to patients in Taiwan and beyond.

Additional NTD 1 billion drives biopharmaceutical innovation in Taiwan

     At its 70th anniversary celebration today, AstraZeneca is proud to announce NTD 1 billion in additional investment, which is the biggest publicly declared commitment to biopharmaceutical healthcare in Taiwan. It demonstrates AstraZeneca’s commitment to address the unmet needs in non-communicable diseases, to enable high-value job creation and to advance biopharmaceutical innovation in Taiwan.
      With this investment AstraZeneca intensifies its efforts in biopharmaceutical R&D in Taiwan, by increasing AstraZeneca Taiwan’s average annual clinical research budget from NTD 230m today to over NTD 600m by 2021—nearly 3-fold increase. It also supports the rollout of ten new medicines in the next three years, that each have the potential to transform the lives of patients in Taiwan that suffer from diseases such as ovarian cancer, lung cancer, severe asthma and diabetes. The investment will create 140 new high-quality jobs and boosts employment in the biopharmaceutical industry.
    AstraZeneca knows that scientific leadership doesn’t happen in isolation. Recognizing Taiwan’s research biopharmaceutical research talent and entrepreneurial ambition, AstraZeneca is honored to sign a Letter of Intent with BioHub Taiwan, the incubator of the newly established National Biotechnology Research Park in Taipei’s Nangang district and Program for Translational Innovation of Biopharmaceutical Development-Technology Supporting Platform Axis (TSPA). Both organizations aspire to work together to develop Taiwanese R&D talent, attract more investment to the biopharmaceutical industry and increase Taiwan’s profile as a biomedical R&D hub.
    Simon Manners, Company President, AstraZeneca Taiwan: ““AstraZeneca is proud to be one of the earliest companies present in Taiwan as well as a cornerstone of healthcare in Taiwan for 70 years. Our new investment and Letter of Intent with the BioHub & TPSA signify our continuous commitment to patients in Taiwan and will support the development of innovative solutions to healthcare challenges in Taiwan for the next 70 years and beyond.”
    Tonight, George Hollingbery, UK Minister of State for Trade Policy, Wang Mei-Hua, Vice Minister, Ministry of Economic Affairs and Chen Shih-Chung, Minister of Health and Welfare, will attend the 70th Anniversary Celebration of the AstraZeneca in Taiwan.
      George Hollingbery, the UK Minister of State for Trade Policy said “Taiwan and the UK share the common problem of increasingly ageing populations.  We need to work together to tackle the challenges that this brings about.  It is vital that we work alongside British companies like AstraZeneca to ensure that the drugs we need to address these challenges can reach patients quickly.”
   Wang Mei-Hua, Vice Minister, Ministry of Economic Affairs said: “I would like to thank AstraZeneca for its continuous investment and operation in Taiwan over the past few decades to assist in the development of Taiwan's biotechnology and pharmaceutical industry. I look forward to seeing AstraZeneca continue to invest in R&D in Taiwan and become an important partner for the development of biotechnology in Taiwan.”